Recruiting NCT06259890
Influence of Sodium Intake in spondyLoarthriTes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: measurement of salt intake.
- Who it may be relevant to
- Registry conditions: Spondyloarthritis, Axial, Arthritis, Psoriatic. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.
Overview
The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.
Interventions
- Other measurement of salt intake
measurement of salt intake without intervention
Primary outcome measures
- sodium intake [Time frame: day of inclusion, monday and tuesday following]
Eligibility criteria
Inclusion criteria
- patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis
- women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)
Exclusion criteria
- patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
- current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old.
- patients on systemic corticosteroids with corticosteroid therapy > 10 mg prednisone equivalent
- pregnant woman
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
France · 4 centers
- CHU Besançon — Besançon
- CHD Vendée — La Roche-sur-Yon
- CHU St Etienne — Saint-Etienne
- Hôpital Nord Franche-Comté — Trévenans
Identifiers
NCT: NCT06259890 · 2023/807